Spring direct naar de hoofdnavigatie of de inhoud
‘IP is the link between advanced knowledge and financial result.’
Martin Klok

Martin Klok

  • Chemistry
  • European and Dutch Patent Attorney, European Patent Litigator
  • Valuation specialist
  • Partner

Prior to working at V.O., Martin Klok was active as a research scientist in organic and physical chemistry. His research activities included functional molecular systems such as fuel cells and photo-active compounds for use in molecular nanotechnology, as well as the chemistry of food and health.

Continue reading

As a patent attorney, Martin primarily focuses on the drafting of applications, arguing patentability, and litigation. He is an active AIPPI member, with activities mainly in the field of pharmaceutical products. His direct experience with research and chemistry, in combination with his understanding of patent law, ensures efficient communication with both inventors, specialists and lawyers. Martin’s work is characterized by a thorough insight into the working of an invention, an eye for detail, and swift understanding of technical relevance, as well as by a social attitude. A particular focus of Martin’s work as a patent attorney is on pharmaceutical products, food and nutraceuticals.

In his capacity as European Patent Litigator, Martin is allowed to act as UPC representative.

Working experience

  • Patent Attorney, V.O. (2011-present)
  • Senior scientist, Dutch Food and Consumer Product Safety Authority
  • University of Groningen; University Council
  • Grasp, Groningen PhD community; board position
  • Research intern, Toshiba RDC, Shin-Kawasaki, Japan

Education

  • PhD in Organic and Physical Chemistry, University of Groningen
  • Japanese language and business culture, Japan Prizewinners Programme, University of Leiden and Japan-Netherlands Institute
  • MSc in Organic Chemistry, University of Groningen

Directories

  • “Recently, pharmaceutical litigation by patent attorneys such as Jetze Beeksma and Martin Klok for research-based industry has dominated more than in previous years. Both partners are stars in the Dutch patent scene” (JUVE Patent 2024).
  • Featured as a patent attorney with technical specialty: pharma and biotechnology  (JUVE Patent 2024)
  • The Netherlands Practitioner of the Year (Managing IP 2024)
  • Recommended individual (JUVE Patent 2021, 2022, 2023, 2024)
  • “Martin Klok was […] highly visible. He is active in several cases alongside Freshfields Bruckhaus Deringer for Novartis. But his greatest success was the PI case for Bristol-Myers Squibb against generics manufacturers over blood-clot drug apixaban, together with Hogan Lovells”(JUVE Patent 2023)
  • Recognized as ‘Notable Practitioner’ (2020, 2021, 2022, 2023, 2024, 2025) by Managing IP
  • “Rising star Martin Klok is ‘incredibly dedicated to understanding issues and distilling relevant information’.” (IP Stars Handbook MIP, 2017)
  • Highlighted as ‘exceptional attorney’ by IP Stars Handbook MIP, 2016
  • Martin Klok is complimented for his ability to “understand the real detail” of an application. “He is one of those guys who really can dig into the details and has a grasp of a huge volume of information, the sort of person you like to have at the table because when you have a question he’s on top of it. It’s clear he knows the file better than the attorneys on the other side do.” (IP Stars Handbook MIP, 2014)

Publications

  • Co-author of Experimental Use and Bolar Exemptions, in the AIPPI Law series (ISBN 9789403518695), 2025.
  • Martin Klok, Senne Plessers: Journal of Towa Instuitute of Intellectual Property, Vol 17, no 3, page 55: “G 1/23: why even “black box” product scan block your patent”.
  • Martin Klok (partner, V.O. Patents & Trademarks), “User statistics on the European patent landscape”; Journal of Towa Institute of Intellectual Property, Vol. 17. No. 1, pg 50-51 (2025).
  • AIPPI Law Series Vol. 5 – Antibody Patenting: A Practitioner’s Guide to Drafting, Prosecution and Enforcement (Jürgen Meier and Oswin Ridderbusch, ed), Chapter 5, “The Netherlands”. ISBN 978-94-035-1073-6 (2019).
  • “Verification of the absence of additives on “free of additive” labeled food products”, (Dutch, 2011).
  • “Verification of the absence of allergens in “free of allergen” labeled food products”, (Dutch, 2011).
  • “Fatty acid composition of traditional and industrial bakery products”, (Dutch, 2010).
  • “Ultrafast Light-Driven Nanomotors Based on an Acridane Stator”, J. Org. Chem. 2010, 75, 666–679. DOI: 10.1021/jo902207x.
  • “Motors for use in molecular nanotechnology” (PhD-thesis, Groningen, 2009).
  • “Motors for molecular nanotechnology” (Dutch), Dutch Physics Magazine 2009, 75 (10), 16.
  • “Kinetic analysis of the rotation rate of light-driven unidirectional molecular motors”, Phys. Chem. Chem. Phys., 2009, 11, 9124-9131. DOI: 10.1039/B906611J.
  • “The influence of viscosity on the functioning of molecular motors”, Faraday Discuss. 2009, 143, 319-334. DOI: 10.1039/B901841G.
  • “Light-driven rotary molecular motors: an ultrafast optical study”, Phys. Stat. Sol. (C) 2009, 6 (1), 181–184. DOI: 10.1002/pssc.200879808.
  • “New Mechanistic Insight in the Thermal Helix Inversion of Second-Generation Molecular Motors”, Chem. Eur. J. 2008, 14, 11183-11193. DOI: 10.1002/chem.200800969.
  • “MHz Unidirectional Rotation of Molecular Rotary Motors”, J. Am. Chem. Soc. 2008, 130, 10484 – 10484. DOI: 10.1021/ja8037245. Highlighted in Nature Chem., 2008, DOI: 10.1038/nchem.45.
  • “Rate Acceleration of Light-Driven Rotary Molecular Motors”, Adv. Funct. Mater. 2007, 17, 718–729. DOI: 10.1002/adfm.200601025.

Professional & Community Activities

  • Member of the IP Valuation Taskforce for ECTA.
  • AIPPI, Vice Chair of the standing committee on Pharma. In 2024, this committee was awarded the AIPPI Team Excellence Award.

Languages

  • English
  • Dutch
  • German
  • French

Also see these experts

Otto Oudshoorn

Otto Oudshoorn

  • European and Dutch Patent Attorney, European Patent Litigator
  • Partner
Huub Maas

Huub Maas

  • European and Dutch Patent Attorney, European Patent Litigator
  • Partner
More experts

News

UPC anti-anti-suit injunctions as interim measures: Munich Local Division in Huawei v Netgear (UPC_CFI_791/2024)

In its Order of 11 December 2024 in UPC_CFI_791/2024 (Munich Local Division), the Unified Patent Court (UPC) granted an ex parte anti-anti-suit/anti-enforcement injunction (AASI/AAEI) to prevent steps in US proceedings that were said to obstruct UPC patent enforcement. The decision is noteworthy for its articulation of the UPC’s jurisdictional basis and the procedural framework for […]Continue reading

R 0016/23: the Enlarged Board confirms the mandatory nature of oral proceedings upon request under Article 116(1) EPC 

In R 0016/23 (Enlarged Board of Appeal, 21 November 2025), the Enlarged Board set aside a Legal Board of Appeal decision which had dismissed an appeal without holding requested oral proceedings. The decision is a clear statement that efficiency and “timely legal certainty” cannot, in themselves, justify restricting the scope of Article 116(1) EPC when […]Continue reading

Medical-device infringement and “standard use”: LD Munich on lege artis use and conditional revocation counterclaims (UPC_CFI_628/2024) 

In its decision on the merits in UPC_CFI_628/2024 (with the related revocation counterclaim UPC_CFI_125/2025), the Munich Local Division of the Unified Patent Court (UPC) addressed two practically relevant issues:Continue reading